Technologies for the Development of Next Generation Adjuvanted Vaccines
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: closed (28 February 2021) | Viewed by 19055
Special Issue Editor
Interests: vaccine adjuvants and mechanism of action; single-dose vaccines; malaria vaccine development; adjuvant-induced inflammation pathways
Special Issue Information
Dear Colleagues,
The recent global emergence of infectious disease outbreaks has emphasized the critical need for novel strategies to combat the spread of a pathogen. In the age of subunit vaccine platforms, the advancement of new technologies that can generate a potent immune response while retaining a good safety profile is a pre-requisite for the development of next generation vaccines.
Vaccine adjuvants can be a powerful tool in new vaccine development, both for established and for emerging pathogens, enabling us to address issues such as subpopulations with impaired immune responses, or the need for vaccine dose-sparing. Adjuvants are often classified into delivery systems and immunopotentiators. However, it is becoming increasingly clear that in the future, most advantageous vaccine formulations will need to combine both qualities: optimal cell targeting for vaccine uptake and the appropriate stimulation of the immune system to induce a lasting and effective response.
This Special Issue focuses on novel technologies addressing vaccines and adjuvant formulation and delivery, the use of advanced (multicomponent) adjuvants, controlled antigen release approaches and the routes of administration. It also includes process development for the scaling up of manufacturing, and the considerations of the key attributes of vaccine development in a pandemic scenario.
Dr. Anita Milicic
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel vaccine adjuvants
- vaccine carriers
- vaccine/adjuvant formulation
- immune mechanisms
- adjuvants for different population groups
- micro- and nano-technologies
- process development for scaling up
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.